NCT00112034已完成4 期
A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 350
- 试验地点
- 2
- 主要终点
- Brain MRI lesion activity measured by the combined number of T2-hyperintense lesions at Month 12 that are new or enlarged since Baseline
研究概览
简要总结
The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients with continued disease activity on AVONEX monotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 55, inclusive
- •Diagnosis of MS
- •A relapsing-remitting course
- •Expanded Disability Status Scale (EDSS) score 0.0-5.5 inclusive at Baseline
- •Currently receiving AVONEX® therapy
- •Treated with AVONEX® for at least 6 consecutive months prior
- •Breakthrough disease (clinical relapse or gadolinium-enhancing MRI lesion) during the prior 12 months, at least 6 months after initiating AVONEX therapy.
排除标准
- •History of cirrhosis, chronic hepatitis, or currently active hepatitis
- •History of poorly-controlled hypertension, diabetes mellitus, or peptic ulcer disease
- •History of aseptic bone necrosis, osteoporosis, or osteoporosis-related bone fracture
- •History of steroid-induced psychosis.
- •History of or abnormal laboratory results indicating significant illness
- •History of severe allergic or anaphylactic reactions or known drug hypersensitivity or intolerance to MTX, IVMP, or AVONEX®.
- •History of allergy to albumin
- •History of any episode of suicidal ideation or severe depression within 3 months of the Screening Visit.
- •History of seizure within 3 months prior to the Screening Visit.
- •Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS
- •MS relapse with onset within 60 days prior to the Baseline Visit
- •Any metallic or electronic material or device in the body, or condition that precludes the subject from undergoing MRI with gadolinium administration
- •A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days of the Screening Visit
- •Abnormal blood tests, performed at the Screening Visit, which exceed any of the limits defined by the study.
结局指标
主要结局
Brain MRI lesion activity measured by the combined number of T2-hyperintense lesions at Month 12 that are new or enlarged since Baseline
effectiveness of AVONEX® and IVMP plus MTX in trying to reduce lesion activity on brain MRI
次要结局
- Gadolinium enhancing lesion number on brain MRI, relapse rate, MS Functional Composite change, whole brain atrophy progression
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT00030966Biogen1,200
终止
2 期
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionChronic Hepatitis C Virus InfectionNCT01080222Vertex Pharmaceuticals Incorporated152
已完成
2 期
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT03662542Janssen Research & Development, LLC214
已完成
3 期
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)Diabetes Mellitus, Type 2NCT00728351Novartis Pharmaceuticals317
已完成
1 期
A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy VolunteersHealthy VolunteersNCT01119677Biogen120